Posted on Leave a comment

Director of the US Biomedical Research and Development Bureau “fired”, suspected of offending Trump and getting revenge

Rick Bright, director of the Biomedical Advanced Research and Development Agency (BARDA) under the US Department of Health, was suddenly expelled. Bright expressed his belief that he was retaliated against because he objected to President Trump’s proposal that the new coronary pneumonia patients take the old drug “hydroxychloroquine” (also known as quinine) to treat malaria.

The director of the US Biomedical Research and Development Bureau “was fired”, suspecting that he offended Trump and was retaliated against. 
AP

Bright issued a statement saying that he was notified on Tuesday that his position as director has been replaced and that he will be transferred to other positions. The Bureau of Advanced Research and Development in Biomedicine is responsible for the development of drugs against the new coronary pneumonia epidemic, and Bright has expressed his opinion, asking for careful verification of whether “Quining” can really cure this disease, and it is unknown whether it caused him to quit the reason.

Bright said: “When I plan to study all feasible options and find an effective treatment” outside the box “, I correctly resist the provision of an unlicensed drug to the American public.” He emphasized that it is obvious that there is no There is scientific evidence to prove that “quinine” can effectively deal with this disease, but the US government has praised those drugs as “magic pills.” The Ministry of Health responded that Bright was a public-private partner agency that was deployed to announce the new establishment last week. That institution is under the jurisdiction of the National Institutes of Health.

Bright is an expert in vaccines and treatments. In 2016, he was appointed as Director of the Advanced Research and Development Bureau of Biomedicine. At that time, Trump had not yet taken office as president. The U.S. Department of Veterans Affairs (VA) published an analysis report recently, stating that “quinine” is not beneficial for the treatment of new coronary pneumonia, but may cause patients to face a greater risk of death. , 97 people were arranged to take “Quining” with standard medical care, resulting in 28% deaths. Another 158 patients did not take “quinine” and the mortality rate was 11%.

Leave a Reply

Your email address will not be published. Required fields are marked *